Daunorubicin-GnRH-III bioconjugates have recently been developed as drug delivery systems with potential applications in targeted cancer chemotherapy. In order to improve their biochemical properties, several strategies have been pursued: (1) incorporation of an enzymatic cleavable spacer between the anticancer drug and the peptide-based targeting moiety, (2) peptide modification by short chain fatty acids or (3) attachment of two anticancer drugs to the same GnRH-III derivative. Although these modifications led to more potent bioconjugates, a decrease in their solubility was observed. Here we report on the design, synthesis and biochemical characterization of daunorubicin-GnRH-III bioconjugates with increased solubility, which could be achieved by incorporating oligoethylene glycol-based spacers in their structure. First, we have evaluated the effect of an oligoethylene glycol-based spacer on the solubility, enzymatic stability/degradation, cellular uptake and in vitro cytostatic effect of a bioconjugate containing only one daunorubicin attached through a GFLG tetrapeptide spacer to the GnRH-III targeting moiety. Thereafter, more complex compounds containing two copies of daunorubicin, GFLG spacers as well as Lys(nBu) in position 4 of GnRH-III were synthesized and biochemically characterized. Our results indicated that all synthesized oligoethylene glycol-containing bioconjugates had higher solubility in cell culture medium than the unmodified analogs. They were degraded in the presence of rat liver lysosomal homogenate leading to the formation of small drug containing metabolites. In the case of bioconjugates containing two copies of daunorubicin, the incorporation of oligoethylene glycol-based spacers led to increased in vitro cytostatic effect on MCF-7 human breast cancer cells.
INTRODUCTION
Tumor targeting with peptides whose receptors are highly expressed on cancer cells is a modern and promising oncological approach, which may significantly decrease the side effects of classical chemotherapy. The application of such peptides as carriers/targeting moieties in a bioconjugate with chemotherapeutic agents can provide a specific receptormediated drug delivery. Furthermore, the slow release of the drug or the intracellular formation of active drug containing metabolites may enhance the therapeutic window of the bioconjugates, in comparison with the administration of free chemotherapeutic agents [1] [2] [3] [4] .
A promising targeting moiety to be used for the preparation of anticancer drug delivery systems is the hypothalamic decapeptide gonadotropin-releasing hormone (GnRH). In particular, the natural isoform GnRH-III (<EHWSHDWKPG-NH 2 , where <E is pyroglutamic acid) isolated from the sea lamprey (Petromyzon marinus) [5, 6] is suitable for this purpose, owing to its binding to the GnRH receptors [7] , found to be highly expressed on various types of cancer cells [3, 8] . Moreover, GnRH-III exerts a direct antiproliferative effect on cancer cells [9, 10] and has lower endocrine activity than human GnRH [3, [11] [12] [13] . Furthermore, it has been shown that the modification of lysine in position 8 of GnRH-III did not result in the loss of its biological properties [9] ; thus, in our previous studies, the side chain of 8 Lys was employed as a conjugation site for the formation of symmetric GnRH-III dimers and anticancer drug-peptide bioconjugates [14, 15] . A panel of anticancer drug-GnRH-III derivative bioconjugates was designed, synthesized and biochemically characterized in our laboratories [16] [17] [18] [19] [20] [21] . The most promising compounds contained daunorubicin (Dau) attached via oxime linkage to the ε-amino group of 6 an additional Lys attached to the side chain of 8 Lys. Most of these compounds showed higher in vitro cytostatic effect and uptake into cancer cells, as well as increased enzymatic stability than the bioconjugates containing only one anticancer drug [19, 23] . However, the acylation of lysine in position 4 with fatty acids, the incorporation of a second anticancer drug in a bioconjugate, as well as the presence of a hydrophobic GFLG tetrapeptide spacer led to decreased solubility of the bioconjugates in aqueous buffers and cell culture media.
It has previously been shown that the addition of an ethylene glycol-based spacer may result in cytotoxic bioconjugates with elevated solubility [24] [25] [26] or increased stability in circulation, allowing a stable accumulation in the tumor [27] . Thus, the incorporation of an oligoethylene glycol-based spacer may also provide increased solubility to oxime bond-linked
Dau-GnRH-III derivative bioconjugates.
On the basis of these previous findings, in the study reported here we aimed to investigate the effect of an oligoethylene glycol-based spacer on the solubility and biochemical properties (i.e., enzymatic stability/degradation, in vitro cytostatic effect) of (1) a bioconjugate in which the anticancer drug daunorubicin was attached via oxime bond, through a GFLG tetrapeptide spacer, to the GnRH-III targeting moiety, and of (2) bioconjugates containing two molecules of daunorubicin attached to a GnRH-III derivative in which 4 Ser was replaced by Lys(nBu). In the latter bioconjugates, a GFLG spacer was incorporated or not between the anticancer drug and GnRH-based targeting moiety.
Our results indicate that appropriate oligoethylene glycol derivatives may enhance not only the solubility, but also the in vitro cytostatic effect of daunorubicin-GnRH-III derivative bioconjugates, in particular of compounds containing two Dau molecules. Moreover, the incorporation of several structural and functional elements in a bioconjugate is a promising strategy that may result in increased antitumor activity.
MATERIALS AND METHODS

Chemicals
Amino acid derivatives, Fmoc-8-amino-3.6-dioxaoctanoic-acid (Fmoc-EG 2 ) and RinkAmide MBHA resin were purchased from Iris Biotech GmbH (Marktredwitz, Germany),
while Rink-Amide ChemMatrix resin was from PCAS BioMatrix Inc. (Quebec, Canada).
Benzotriazol- 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 The synthesis of GnRH-III[ 8 Lys with 2% TFA in DCM (6 x 5 min), followed by the coupling of Fmoc-EG 1 . After Fmoc deprotection with 2% DBU, 2% piperidine in DMF, the synthesis continued with building the GFLG tetrapeptide spacer and coupling of 5 equiv of bis-BocAoa-OH, after preactivation with PyBOP/NMM (1 h coupling time). The aminooxyacetylated peptides were cleaved from the resin using a mixture of 95% TFA, 2.5% TIS and 2.5% water (v/v/v) in the presence of 10 equiv of free aminooxyacetic acid as a "carbonyl capture" reagent [28] , for 2.5 h at room temperature, precipitated with ice-cold diethyl ether, washed three times with diethyl ether and solubilized in 100% acetic acid prior to freeze drying. The crude products were purified by semipreparative RP-HPLC and chemically characterized by analytical HPLC and mass spectrometry.
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The conjugation of daunorubicin to the aminooxyacetylated GnRH-III derivatives was carried out in 0.2 M sodium acetate buffer, pH 5.0, at a peptide concentration of 10 mg/mL.
Daunorubicin was used in 30% excess compared to the aminooxyacetylated derivatives of GnRH-III. The reaction mixtures were stirred at room temperature for 24 hours and then subjected to RP-HPLC purification. The purified bioconjugates were characterized by analytical RP-HPLC and mass spectrometry. After completing the synthesis of the protected decapeptide, the Dde-protecting group of the ε-NH 2 group of 4 Lys was removed by 4% hydrazine in DMF (12 x 5 min); after that, the n-butyration of the free ε-NH 2 group was achieved using 3 equiv n-butyric anhydride : DIEA both α-and ε-amino groups of lysine and then the resin was divided into two portions. To one of them, bis-Boc-Aoa-OH was coupled for 2 h using DIC/HOBt coupling reagents (3 equiv each to the amino groups) (in the case of compound 5). In the case of compound 6, two copies of the GFLG tetrapeptide spacer were built and then bis-Boc-Aoa-OH was coupled as described before. In the other two cases, the bis-Boc-Aoa-OH was attached directly (for compound 3) to the amino groups of Lys in the branch or to those of the incorporated GFLG spacers (for compound 4), as mentioned above.
Synthesis of GnRH
The aminooxyacetylated peptides were cleaved from the resin, worked-up, purified and chemically characterized as mentioned above and after that the conjugation of daunorubicin was performed. The reaction mixtures were subjected to RP-HPLC purification and the purified bioconjugates were characterized by analytical RP-HPLC and mass spectrometry.
High performance liquid chromatography (HPLC)
The bioconjugates 1 and 2 were purified on a SpectraSystem (Thermo Fisher Scientific, Daunorubicin-GnRH-III derivative bioconjugates 3-6 were purified on a KNAUER 2501 HPLC system (H. Knauer, Bad Homburg, Germany) using a semipreparative Phenomenex Luna C18 column (250 mm x 10 mm) with 10 µm silica (100 Å pore size) (Torrance, CA). 
Mass spectrometry (MS)
Electrospray ( 
Solubility determination of the bioconjugates using an HPLC-based approach
The solubility of the bioconjugates in DMEM cell culture medium was determined as follows: a 2 mM aqueous solution of each bioconjugate was diluted with cell culture medium to obtain a 100 µM concentration. This solution was incubated for 15 min at room temperature and then centrifuged for 15 min at 13000 rpm. From the obtained supernatant, an appropriate volume, which should contain 30 µg of bioconjugate -assuming that it would have been completely soluble at a concentration of 100 µM -was taken and diluted to a volume of 500 µL with 0.1% TFA in water (HPLC eluent A). A reason for diluting the solution with eluent A was also to adjust the pH to 2.5, before analyzing the sample by analytical RP-HPLC. In the case of bioconjugates 1 and 2, the analyses were performed on an UltiMate 3000 HPLC system (Dionex, Idstein, Germany) as described above. The bioconjugates containing two copies of daunorubicin were analyzed on an Exformma EX1600
HPLC system (Wincom, Shanghai, China) using a Zorbax SB-C18 column ( 
Stability of GnRH-III[( 8 Lys(Dau=Aoa-GFLG-EG 1 )] bioconjugate in human serum
The stability of GnRH-III[( 8 Lys(Dau=Aoa-GFLG-EG 1 )] in 90% human serum was determined as previously reported for GnRH-III[( 8 Lys(Dau=Aoa-GFLG)] [18] . Briefly, the bioconjugate was first dissolved in water to obtain a stock solution of 100 µM concentration, which was added to human serum, so that the final bioconjugate concentration was 10 µM.
The mixture was incubated at 37°C and aliquots were taken after 5 min and 24 h. After quenching the reactions with acetic acid, the large human serum proteins were removed using
Microcon centrifugal filter devices with 10 kDa cut-off (Millipore Corporation, Bedford, MA, 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 USA), followed by the LC-MS analysis of the lower molecular weight fraction. Two control experiments were also performed: (1) 90% human serum and (2) an aqueous solution of the bioconjugate (c = 10 µM) were incubated at 37°C and aliquots taken after 5 min and 24 h were analyzed by LC-MS.
Degradation of oxime bond-linked Daunorubicin-GnRH-III derivative bioconjugates in the presence of rat liver lysosomal homogenate
The rat liver lysosomal homogenate was prepared as previously described [16, [18] [19] [20] [21] . The 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 (Sigma Ltd.). The cell culture was maintained at 37°C in a humidified atmosphere with 5% CO 2 .
Cellular uptake of bioconjugates 1 and 2 determined by flow cytometry
To determine the cellular uptake of bioconjugates 1 and 2, MCF-7 human breast cancer cells were plated at a number of 1 x 10 5 cells per well on 24-well plates in 1 mL complete medium. After 24 h incubation at 37°C, cells were centrifuged for 5 min at 1000 rpm and the supernatant was removed. Thereafter, 250 µL of bioconjugate solutions (in serum-free medium) were added onto the cells in the 0.16 µM to 100 µM concentration range. Control cells were treated with serum-free medium. Cells were incubated with bioconjugate solutions at 37°C for 6 h. After that, the solutions were removed from the cells, 100 µL trypsin were added per well and incubated for 10 min at 37°C. After adding 900 µL of HPMI (glucose, 
In vitro cytostatic effect of the bioconjugates determined by MTT assay
The in vitro cytostatic effect of the bioconjugates was determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay (MTT assay). One day before the treatment, 5 x 10 3 MCF-7 cells per well were plated on 96-well plates. After 24 h incubation at 37°C, the cells were treated for 6 h with the bioconjugates used in the 0.256-100 µM concentration range. The solutions were prepared in serum-free medium. Cells treated for 6 h with serum-free medium were used as a control. After treatment and incubation, cells were 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 washed twice with serum-free medium and cultured in serum containing medium for 72 h. On the fourth day, the MTT assay was performed. MTT was added to each well (final concentration: 367 µg/mL) and during 3.5 h incubation at 37°C, purple crystals were formed by mitochondrial dehydrogenase enzyme present in the living cells. After that, cells were centrifuged for 5 min at 2000 rpm and the supernatant was removed. The crystals were dissolved in 100 µL DMSO and the optical density (OD) was determined at λ = 540 and 620 nm using an ELISA Reader (Labsystems MS reader, Helsinki, Finland). OD 620 was subtracted from OD 540 and the percentage of cytostasis was calculated using the following equation:
where OD treated and OD control correspond to the optical densities of treated and control cells, respectively. Cytostasis % was plotted as a function of concentration, fitted to a sigmoid curve and the 50% inhibitory concentration (IC 50 ) value was determined from these curves.
RESULTS AND DISCUSSION
Oligoethylene glycol-modified bioconjugate containing only one daunorubicin attached through a GFLG tetrapeptide spacer to the GnRH-III targeting moiety [16, 18] . These fragments were labeled in all mass spectra with an asterisk.
Synthesis and chemical characterization of GnRH-III based bioconjugates containing only one daunorubicin
Solubility of bioconjugates 1 and 2 in cell culture medium determined by an HPLC-based approach
Solubility determinations are generally based on weight measurements [29] , which are not precise in the case of low amounts of sample. To evaluate the influence of the oligoethylene glycol-based spacer on the solubility of oxime bond-linked Dau-GnRH-III derivative bioconjugates in cell culture medium, an RP-HPLC based approach was established in the present study. This method was based on AUC determinations and it only required a standard curve, which was first recorded using different concentrations of a particular bioconjugate dissolved in water. Thereafter, a sample which should contain a certain amount of bioconjugate (30 µg, assuming that it would completely be soluble) was analyzed ( Figure S3 in Supporting Information).
Our results indicated that the incorporation of an oligoethylene glycol-based spacer led to a bioconjugate 2 with significantly higher solubility than 1 (78.8% vs. 42.5%, particularly in lysosomes, in order to release the free drug or to generate drug-containing metabolites displaying antitumor activity.
Degradation of bioconjugate 1 in the presence of rat liver lysosomal homogenate has previously been reported [18] and results are summarized in Figure 1A and Table S1 . The degradation of bioconjugate 2 was investigated by LC-MS, which led to the identification of several cleavage sites, both within the GFLG spacer and the GnRH-III sequence ( Figure 1B and Table S1 ).
In agreement with our previous findings, no free daunorubicin was detected by LC-MS, indicating substantial chemical and enzymatic stability of the oxime bond [16, 18] . The smallest drug containing metabolite generated in the case of both bioconjugates in the presence of lysosomal enzymes and identified by mass spectrometry was Dau=Aoa-Gly-OH (m/z 658.1 (1+)) ( Figure S4 in Supporting Information). We have previously shown that this drug containing metabolite was able to bind to DNA in vitro, thus providing an explanation for the antitumor activity of the bioconjugates. Taken together, these results allow concluding that the oligoethylene glycol-based spacer did not influence the enzymatic degradation of the bioconjugate, in particular when an enzymatic cleavable GFLG tetrapeptide spacer was incorporated in its structure.
Furthermore, the effect of the oligoethylene glycol spacer on the stability of bioconjugate 2 in human serum was also investigated. We have previously reported that various oxime bond-linked Dau-GnRH-III derivative bioconjugates developed in our laboratories, including compound 1, were stable in human serum for at least 24 h [18, 20] . In the present study, the influence of the oligoethylene glycol-based spacer on the stability of bioconjugate 2 in human serum was determined by LC-MS. After 5 min and 24 h incubation at 37°C, aliquots were taken from the reaction mixture and subjected to MS analysis, which indicated that the incorporation of an oligoethylene glycol-based spacer in the structure of the bioconjugate did not influence its stability in human serum, in comparison with that of compound 1; intact bioconjugate 2 was detectable by mass spectrometry even after 24 h incubation with human serum ( Figure 2A ). As described in the experimental section, two control experiments were performed, in which both 90% human serum and an aqueous solution of the bioconjugate were incubated at 37°C and analyzed by LC-MS, in order to facilitate the interpretation of mass spectrometric data and to also assess the chemical stability of the bioconjugate ( Figures   2B and 2C ).
Cellular uptake of bioconjugates 1 and 2 determined by flow cytometry
Based on the fluorescence properties of daunorubicin [18] , the uptake of bioconjugates 1 and 2 by MCF-7 human breast cancer cells was determined by flow cytometry, at different bioconjugate concentrations (between 0.16 and 100 µM). As shown in Figure 3 , both compounds were taken up by MCF-7 cells in a concentration dependent manner; however, no significant differences could be observed in the entire concentration range. Very slight differences could be determined at a concentration of 4 µM, the oligoethylene glycol containing compound being characterized by an elevated cellular uptake (Dau positive MCF-7 cells: 8.6% vs. 6.0%).
Cytostatic effect of bioconjugates 1 and 2
The in vitro cytostatic effect of bioconjugates 1 and 2 was evaluated on MCF-7 human on colon carcinoma bearing mice, while no signs of toxicity were detected on healthy mice [17, 30] . Moreover, compared to free Dau, the bioconjugate had broader therapeutic window.
Taken together, these results support the concept of targeted cancer chemotherapy, namely increased selectivity and decreased peripheral toxicity of conjugated anticancer drugs.
Oligoethylene glycol modified GnRH-III based bioconjugates containing two copies of daunorubicin
Synthesis and chemical characterization of GnRH-III based bioconjugates containing two copies of daunorubicin
We have previously shown that the attachment of two Dau molecules to the same GnRH- 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 aimed to combine the structural elements mentioned above in a single bioconjugate; i.e., the 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58 Figure 4 .
Solubility determination of bioconjugates 3-6 using an HPLC-based approach
The solubility of bioconjugates 3-6 containing two Dau copies was determined by the HPLC-based approach described above. As summarized in Table 2 , incorporation of the oligoethylene glycol based spacer significantly improved the solubility of the compounds, from 16.4% (bioconjugate 3) to 45.1% (bioconjugate 5) and from 1.6% (bioconjugate 4) to 10.6% (bioconjugate 6), respectively.
Enzymatic degradation of bioconjugates 3-6 in the presence of lysosomal enzymes
The degradation of butyrated bioconjugates 3-6 in the presence of lysosomal enzymes was determined by LC-MS, as described above. Cleavage sites were identified within the GFLG spacer (bioconjugates 4 and 6) and GnRH-III sequence (bioconjugates 3-6), as well.
Furthermore, the isopeptide bond between 8 Lys and the additional Lys in the braches was We have previously shown that both H-Lys(Dau=Aoa)-OH and Dau=Aoa-Gly-OH could efficiently bind DNA in vitro, this result providing an explanation for the cytostatic effect and mechanism of action of the bioconjugate [18] . From the bioconjugate 3, in which Dau=Aoa was directly attached to both amino groups of the additional Lys coupled to 8 Lys of GnRH-III, a fairly large fragment was identified as being the smallest drug containing metabolite produced by lysosomal enzymes. This finding may explain its lower cytostatic effect (Table   3 ). In bioconjugate 5, Dau=Aoa is connected to the ethylene glycol moiety and Dau=Aoa-EG 2 -OH was detected by mass spectrometry as the smallest drug containing metabolite.
In vitro cytostatic effect of bioconjugates 3-6
The in vitro cytostatic effect of bioconjugates 3-6 was determined on MCF-7 human breast cancer cells by MTT assay (Table 3 ). The incorporation of the GFLG tetrapeptide spacer and/or oligoethylene glycol moiety led to an increased antiproliferative effect of we found that the incorporation of a GFLG spacer led to elevated antitumor activity, a result that may be explained by the size of the drug containing metabolites produced in the presence of lysosomal enzymes. On the basis of these results, it can be concluded that incorporation of several structural and functional elements in a bioconjugate may provide improved physicochemical and biological properties.
CONCLUSIONS
In the present work, GnRH-III and its derivative modified in position 4 by Lys(nBu) were employed as targeting moieties to which one or two copies of Dau were attached via oxime bond, leading to the formation of drug delivery systems with potential applications in targeted cancer chemotherapy. In order to facilitate the drug release, a cathepsin B-cleavable GFLG tetrapeptide spacer was also incorporated in some of the bioconjugates. Furthermore, oligoethylene glycol-based spacers were used with the primary goal of improving their solubility and biological properties (e.g., the antiproliferative activity).
In the case of a bioconjugate containing only one Dau attached through a GFLG spacer to the native GnRH-III, the incorporation of an oligoethylene glycol spacer led to enhanced solubility in cell culture medium, as determined by an HPLC-based approach. However, no significant influence of the oligoethylene glycol moiety on the in vitro stability/degradation, cellular uptake and cytostatic effect of the bioconjugate was observed.
The incorporation of oligoethylene glycol spacers in the structure of bioconjugates containing two Dau copies attached to GnRH-III[ 4 Lys(nBu)] led to elevated solubility as well.
The degradation of these "multi-drug" bioconjugates in the presence of rat liver lysosomal homogenate was investigated by LC-MS, which indicated that the formation of the smallest drug containing fragments was strongly dependent on bioconjugate structure. Furthermore, the compounds containing the oligoethylene glycol moiety showed enhanced cytostatic effect on MCF-7 human breast cell lines.
Taken together, these results suggest that appropriate oligoethylene glycol derivatives may enhance not only the solubility, but also the in vitro cytostatic effect of Dau-GnRH-III derivative bioconjugates developed as drug delivery systems. In a long term perspective, the incorporation of several structural and functional elements in a bioconjugate is a promising strategy that may result in increased antitumor activity of anticancer drug-peptide bioconjugates, with potential applications in targeted cancer chemotherapy.
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